Catalog No.S7295 Synonyms: RVX-000222
Molecular Weight(MW): 370.4
Apabetalone (RVX-208) is a potent BET bromodomain inhibitor with IC50 of 0.510 μM for BD2 in a cell-free assay, about 170-fold selectivity over BD1. Phase 2.
1 Customer Review
Bromodomain 1 or 2 of BET family proteins is involved in 3T3-L1 adipogenesis. (A) LY294002, RVX208 and JQ1 were applied to differentiating 3T3-L1 from day 2 to day 6. Phenyl acetate (PA), known as a PPAR-γ agonist was used as a positive control. Cells were labeled with ORO (Bar=50nm). (B) Schematic representation of specificity of each chemical inhibitor for Bromodomain BD1 and 2 and quantitative analysis of ORO staining. The IDMR treatment without drugs (CTL) was used to define 100%. Data are reported as means ± sd (n=3); *** p<0.001 vs IDM control; ### p<0.001 vs IDMR control (-)-JQ1); +++ p<0.01 vs IDM of each condition; ns, non significant.
BBRC, 2016, 472(4):624-630.. Apabetalone (RVX-208) purchased from Selleck.
Purity & Quality Control
Choose Selective Epigenetic Reader Domain Inhibitors
|Description||Apabetalone (RVX-208) is a potent BET bromodomain inhibitor with IC50 of 0.510 μM for BD2 in a cell-free assay, about 170-fold selectivity over BD1. Phase 2.|
|Features||First-in-class BD2-selective inhibitor of BET bromodomain and has been tested in Phase II clinical trials for treatment of coronary syndromes and atherosclerosis.|
As a BET bromodomain inhibitor, RVX-208 preferentially binds to the second bromodomain found on BET proteins.  RVX-208, as a stimulator of apolipoprotein (APO) AI gene expression, increases apoA-I and HDL-C in vitro.  
|In vivo||RVX-208 significantly increases serum apoA-I and HDL-C in AGMs, and enhances cholesterol efflux via different pathways. |
|In vitro||DMSO||74 mg/mL (199.78 mM)|
|In vivo||Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
0.5% CMC Na (1N HCl, PH 2.5-3.0)
For best results, use promptly after mixing.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03228940||Not yet recruiting||Fabry Disease||Resverlogix Corp||January 31 2019||Phase 1|Phase 2|
|NCT02586155||Recruiting||Diabetes Mellitus Type 2|Coronary Artery Disease|Cardiovascular Diseases||Resverlogix Corp|PPD|ICON plc|Medidata Solutions||October 2015||Phase 3|
|NCT01863225||Terminated||Dyslipidemia|Coronary Artery Disease||Resverlogix Corp|South Australian Health and Medical Research Institute||May 2013||Phase 2|
|NCT01728467||Completed||Diabetes||Resverlogix Corp|Baker IDI Heart and Diabetes Institute|Nucleus Network Ltd||November 2012||Phase 2|
|NCT01058018||Completed||Atherosclerosis|Coronary Artery Disease||Resverlogix Corp||December 2009||Phase 2|
|NCT00768274||Completed||Dyslipidemia|Atherosclerosis|Acute Coronary Syndrome|Cardiovascular Disease||Resverlogix Corp||September 2008||Phase 1|Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.